ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / IVVD / earnings
IPHA (52) ABOS (38) CGEN (78) DTIL (24) ⌘ Pro Terminal →

Invivyd Inc. (IVVD) Next Earnings Date & Expected ±12.5% Move

$0.58 -3.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.58

Invivyd Inc. (IVVD) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $177.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IVVD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IVVD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Invivyd Inc. (NASDAQ: IVVD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.58 (-3.37% 1D, market cap $177.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IVVD ranks #851 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IVVD compare to IPHA and ABOS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IVVD carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IPHA (Innate Pharma S.A. ADS) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $167.6M) and ABOS (Acumen Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $165.6M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IVVD?
▼

Per IVVD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001832038), Invivyd Inc. generated $53.4M in revenue (+110.5% YoY), -$52.5M in net income, and -$58.3M in free cash flow against $276.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.58 (-0.80%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (3)Whales (12)SEC (5)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.1% Base Target
$3 Bull$1 Base$0 Bear
📬 FREE IVVD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IVVD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY IVVD SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (40% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 36.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$0.72-13.9% Next Q
Q2 (-2Q)
35
Grade E$0.62-1.6% Next Q
Q3 (-1Q)
33
Grade E$0.61-4.9% Next Q
Current
30
Grade E$0.58-9.6% Hist 90D α
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IVVD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IVVD currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.79) and Max Pain ($0.61) forces dealer call-delta covering toward $3.22.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IVVD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IVVD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.07 Expected Swing
$1.00 (-12.5%)Spot $0.58$0.65 (+12.5%)
MODEL EARNINGS SETUP GAUGE

IVVD Quantitative Pre-Earnings Setup: 30/100

Trailing EPS: $4.25 • YoY Revenue Growth: 110.5%

Model Bullish Setup (30/100)Model Risk Weight (70/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$53.4M-$52.5M-$58.3M52%
FY 20242024-12-31$25.4M-$169.9M-$170.6M52%
FY 20232023-12-31$0-$198.6M-$173.2M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IVVD)

  • ✓Walkthrough of IVVD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IVVD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -58.57%▼ DESCENDING CHANNEL
2026-10-30O $0.56H $0.59L $0.54C $0.58VOL 5.37M
RES: $0.97SUP: $0.14SMA50: $0.79SMA200: $1.16
$1.78$1.44$1.10$0.76$0.42RES $0.97SUP $0.14$0.582026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IVVD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IVVD Butterfly Map → + Track IVVD →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +110.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IVVD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IVVD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IVVD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IVVD)

Health Care Rank #851 of 1016 ⚔️ IPHA vs IVVD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IVVD vs. IPHA, ABOS, CGEN, DTIL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Invivyd Inc. (IVVD) ranks #851 by composite RQD confidence (30/100, grade E) and #593 by equity capitalization ($177.4M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with IVVD at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IVVD ACTIVE
Invivyd Inc.
E 30/100 — — -35.0% -3.37% $177.4M Benchmark Subject
IPHA
Innate Pharma S.A. ADS
D+ 52/100 — — — -2.67% $167.6M /ipha-vs-ivvd →
ABOS
Acumen Pharmaceuticals Inc.
D- 38/100 — — -35.0% -90.82% $165.6M /abos-vs-ivvd →
CGEN
Compugen Ltd.
B+ 78/100 5.5x 87.3% 85.0% -2.94% $193.0M /cgen-vs-ivvd →
DTIL
Precision BioSciences Inc.
E 24/100 — — -35.0% -5.11% $205.4M /dtil-vs-ivvd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001832038

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Invivyd Inc. (IVVD) reported GAAP revenue of $53.4M (+110.5% vs. FY2024 revenue of $25.4M ) , GAAP net income of -$52.5M, operating cash flow of -$58.1M, and free cash flow of -$58.3M (+65.8% YoY). On the balance sheet, IVVD closed FY2025 with $276.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $53.4M -$52.5M -$58.1M -$58.3M $276.9M —
FY2024 (FY) 2024-12-31 $25.4M -$169.9M -$170.5M -$170.6M $129.5M —
FY2023 (FY) 2023-12-31 $0 -$198.6M -$173.2M -$173.2M — —

3. IVVD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IVVD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Invivyd Inc. (NASDAQ: IVVD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.58 (-3.37% 1D, market cap $177.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IVVD ranks #851 in composite RQD confidence.

How does IVVD compare to IPHA and ABOS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IVVD carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IPHA (Innate Pharma S.A. ADS) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $167.6M) and ABOS (Acumen Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $165.6M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IVVD?

Per IVVD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001832038), Invivyd Inc. generated $53.4M in revenue (+110.5% YoY), -$52.5M in net income, and -$58.3M in free cash flow against $276.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IVVD trading relative to its 50-day, 200-day, and 52-week technical levels?

IVVD last traded at $0.58 (-3.37% on volume of 5,379,106 shares), positioning the stock -26.58% below its 50-day simple moving average ($0.79) and -50.00% below its 200-day simple moving average ($1.16). Across its 52-week range of $0.53 to $3.07, IVVD sits at the 2.0% percentile with a 14-day RSI of 36.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.65).

IVVD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is IVVD's next earnings date?

Based on SEC filing cadence, Invivyd Inc. (IVVD)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is IVVD stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for IVVD, spanning a range between $1 and $0.65.

Direct Sub-Reports: IVVD RQD Cockpit IVVD 12M Forecast IVVD Earnings & Move IVVD Dividends & DRIP IVVD Insiders & 13F IVVD Whale Options IVVD Profit Sankey IVVD News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IVVD — Invivyd Inc.: What the Facts Mean to a Prospective Investor

Engine: roarable-bundle-v1
As of: 2026-11-02T15:08:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Invivyd Inc. (IVVD) carries a composite score of 30 / 100 (E — Roarable Strong Sell — Forensic Risk / Avoid).\n- Fundamental Cash Engine (2 / 20): Return on invested capital (ROIC) registers at -35.0% with a free cash flow yield of 0.00% and gross margin of 0.0%.\n- Institutional 13F Whale Flow (12 / 20): Tracks institutional accumulation and dark-pool/options positioning relative to the Biotechnology: Biological Products (No Diagnostic Substances) cohort.\n- Insider & Congressional Conviction (3 / 20): Evaluates open-market Form 4 executive purchases and Congressional PTR disclosures.\n- Macro Regime Fit (8 / 20): Equity beta of 1.00 across the Health Care sector.\n- Forensic Balance-Sheet Shield (5 / 20): Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt-to-Equity of 0.50.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %\n------------------------------\n$0.58$177.4MN/AN/AN/AN/A0.00%1.00$0.53 - $3.07-35.0%

Business & Sector Positioning

Invivyd Inc. (IVVD) is a NASDAQ-listed Health Care issuer operating in Biotechnology: Biological Products (No Diagnostic Substances) with a market capitalization of $0.2B.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Operating within Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), IVVD exhibits an operating margin of -60.0% and net margin of -60.0%. Prospective investors should monitor 2nd-order capex cycles, input cost pass-through in gross margin (0.0%), and valuation discipline (current multiple) relative to free cash flow conversion.

Open Questions for Prospective Investors

  • How sustainable is IVVD's current operating margin (-60.0%) and ROIC (-35.0%) over the next four quarters?\n2. Does the current valuation multiple (current EV/EBITDA) adequately discount macro sensitivity (Beta 1.00) in Biotechnology: Biological Products (No Diagnostic Substances)?\n3. Will upcoming quarterly cash flow conversion support continued balance-sheet strength (Altman Z 0.20)?

IVVD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Invivyd Inc. (IVVD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IVVD Debate Forum (3) ↓
🔴 RISK WATCH Benzinga • 19d ago
Invivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndrome

The Phase 2 FLINTLOCK clinical trial includes the following study features:Randomized, double-blind, placebo-controlled, proof-of-concept studyTests Invivyd’s monoclonal antibody VYD2311, an investigational monoclonal

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IVVD Bull vs. Bear Conversation Board — What's Your Call at $0.58?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IVVD 🐻 67% BEARISH CONVICTION
1. Pick Your Side on IVVD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.51 (-12.1%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IVVD (E • RQD 30/100) a Buy at $0.58?

Welcome to the IVVD (Invivyd Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.49 (-15.5%)
Spot @ $0.58

Pump the brakes on IVVD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IVVD, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Invivyd Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.66 (+13.8%)
Spot @ $0.58

IVVD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IVVD, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.58 (52-wk range $0.53 - $3.07), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%